High dose chemotherapy with stem cell support in gynecological malignancies: Indications and current clinical trials in Germany;Stellenwert der stammzellgestutzten Hochdosischemotherapie in der Behandlung gynakologischer Malignome: Indikationen und aktuelle Studienlage in der Bundesrepublik Deutschland

Zentralblatt fur Gynakologie

Volumn 119, Issue 5, 1997, Pages 195-203

  Nitz, Ulrike ^a,e   Frick, M ^b   Adomeit, A ^a   Jackisch, C ^c   Schwenkhagen, A ^c   Mobus V ^d   Bender, H G ^a  

^a Universitäts Frauenklinik ^*  (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e Oberarztin der Universitats F   (Germany)

Author keywords

breast cancer; clinical trials; high dose chemotherapy; ovarian cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; MELPHALAN; METHOTREXATE; TENIPOSIDE; THIOTEPA; VINCRISTINE; ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOXICITY; FEMALE; GERMANY; GYNECOLOGIC CANCER; HUMAN; REVIEW; STEM CELL; ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METASTASIS; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS;

EID: 0030626973     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Antman K: Dose intensive adjuvant therapy in breast cancer. Dallas, Texas 1994
2. Antmann K, Eder JP, Elias A: Stamp Studies of High Dose Chemotherapy in breast cancer. Autologous Bone Marrow Transplantation Stamp Studies (1996) 377-383
3. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissmann L, Chritchlow J, Schryber SM, Begg C, Teicher BA, et al.: High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol 17 (1990) Suppl 3, 33-38
4. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei ER, Elias A: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13 (1995) 2043-2049
5. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13 (1995) 2483-2489
6. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304 (1981) 10-15
7. Budman DR, Wood W, Henderson IC: Initial findings of CALGB 8541: A dose and dose intensity trial of cyclophosphamide, doxorubicine, and fluorouacil as adjuvant treatment of stage II node positive female breast cancer. Proc ACSO 11 (1992) 29
8. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G, Ragni N, Rosso R, Rugiati S, Rubagotti A: High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14 (1996) 351-356
9. Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, Schiffman K, Bensinger WI: Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 13 (1995) 1714-1719
10. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support [published erratum appears in Cancer 74 (1994) 773]. Cancer 73 (1994) 2157-2167
11. Eder JP, Antman K, Elias A: Cyclophosphamide and Thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 80 (1988) 1221-1226
12. Fenelly D, Schneider J, Spriggs D, Bengala C, Hakes T, Reich L, Barakat R, Curtin J, Moore MAS, Hoskins W, Norton L, Crown J: Dose escsalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor cell mobilisation and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 13 (1995) 1160-1166
13. Gianni AM, Siena S, Bregni M, Di Nicola M, Doderon A, Zambetti M, Orefice S, Salvadori B, Luini A, Greco M, Zucali R, Valagussa P, Bonadonna G: Five-years results of high-dose sequential adjuvant chemotherapy in breast cancer with > 10 positives nodes. Proc Amer Soc Clin Oncol 14 (1995) 54
14. Henderson I, Hayes, Gelman R: Dose-Response in the Treatment of Breast Cancer: A Cirtical Review. J Clin Oncol 6 (1988) 1501-1515
15. Hong Kong Ovarian Carcinoma Study Group: Ngan HYS, Choo YC, Cheung M. Wong LC, Ma HK, Collins R, Fung C, Ng CS, Wong V, Ho HC, Leung P, Wong R, Chan E, Simon MTP, Ho LC, Chan YF: A randomized study of high-dose versus low-dose cis-platinum with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35 (1989) 221-227
16. Hortobagyi GN: High-dose chemotherapy is not established treatment for breast cancer. Los Angeles, CAL: American Society of Clinical Oncology 1995
17. Hryniuk WM, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 (1984) 1281-1287
18. Kaye SB, Lewis CR, Paul J: Randomized study of two doses of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340 (1992) 329-333
19. Klumpp TR, Goldberg SL, Mangan KF, Macdonald JS: High dose cyclophosphamide, etoposide, and carboplatin with autologous stem cell rescue forchemosensitive metastatic and high risk breast cancer. Proc Am J Clin Oncol 13 (1994) 111 oder 245
20. Levin L, Hryniuk W: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5 (1987) 756-767
21. Livingston R, Collins C, Williams M, Thompson R, Rivkin S: Determinants of outcome after consolidation for stage IV breast cancer with cyclophosphamide, etoposide and cisplatin (CEP). Proc Am Soc Clin Oncol 13 (1994) 58 (Abstr. 34)
22. McGuire WP: Ovarian Cancer. New York: Marcel Dekker, Inc 1995
23. McGuire WP, Hoskins W, Brady MF: Cyclophosphamide and Cisplatin compared with Paclitaxel and Cisplatin in Patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
24. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13 (1995) 1589-1599
25. Norton L, Day R: Potential Innovations in Scheduling of Cancer Chemotherapy. Städt. Kliniken, Oldb. 6 (1996) 57-72
26. Norton LA: A Gompertzian modell of human breast cancer growth. Cancer Res 48 (1988) 7067-7071
27. Omura GA, Brady MF, Delmore JE, Long HJ, Look KY, Averette E, Wadler S, Spiegel S: A randomized trial of paclitaxel at 2 dose levels and filgastrim at 2 doses in platinum ptetreated epithelial ovarian cancer: a Gynecologic Oncology Group, SWOG, NCCTG and ECOG Study. Proc. ASCO 15 (1996) 280
28. Peters WP: Five Year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving 10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Clin Oncol 14 (1995) 317 (abstr. 933)
29. Peters WP: Hochdosistherapie beim Mammakarzinom, 1996
30. Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkordy M, Rubin P, Ross, Berry D: A large, prospective, randomized trial of high-dose combination alkylating agents with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy. Proc Am Soc Clin Oncol 15 (1996) 121 oder 149
31. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB: High-Dose Chemotherapy and Autologous Bone Marrow Support as Consolidation After Standard-Dose Adjuvant Therapy for High-Risk Primary Breast Cancer. J Clin Oncol 11 (1993) 1132-1143
32. Rowinsky EK, Mackey MK, Goodman SN: Metaanalysis of paclitaxel dose-response and dose-intensity in recurrent or refractoy ovarian cancer. Proc ASCO 15 (1996) 284
33. Sandherr M, Frickhofen N, Möbus VJ, Schreiner T, Römpp A, Wiesnetz M, Kreienberg R, Herrmann F: Sequential high-dose chemotherapy with peripheral blood progenitor cell support in advanced ovarian and testicular cancer. Proc ASCO 15 (1996) 343
34. Shea TC, Flaherty M, Elias A, et al.: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7 (1989) 651-661
35. Shpall EJ, Cagnoni P, Bearman SI, Purdy MP, Jones R: High-dose therapy with autologous hematopoietic support for the treatment of high-risk breast cancer. Los Angeles: 1995
36. Stemmer SM, Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, Day T, Taffs S, Hami L, Martinez C, Purdy MH, Arron J, Jones RB: High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 14 (1996) 1463-1472
37. Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, McGloskey T: Phase I clinical and pharmacokinetics study of high-dose mitoxantron combinet with carboplatin, cyclophosphamide and autologous bone marrow rescue: High response rate for refractoy ovarian carcinoma. J Clin Oncol 12 (1995) 176-183
38. Tannock IF, Boyd NF, de Boer G: A randomized trial of two dose levels of cyclophosphamide, methotrexat, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6 (1988) 1377-1387
39. Tiersten A, Raptis G, Yao TJ, Ren L, Hamilton N, Damaskus P, Kesselmann E, Reich L, Vahdat L, Fenelly D, Hudis C, Seidman A, Gilewski T, Moynahan M, Baselga J, Sklarin N, Norton L, Crown J: Factors predicting prolonged progression free and overall survival in metastatic breast cancer patients undergoing high-dose chemotherapy with peripheral Proc blood progenitor ceil support. ASCO 15 (1996) 339